GlassScriptPhysician profile
Maribeth Dudley Moore
NPI 1376530758
$6,765.90
in general payments reported to CMS, 2019-2025
30 companies · $821 in 2025
The $821 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $962 · 2020: $1,141 · 2021: $992 · 2022: $916 · 2023: $1,078 · 2024: $855 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,754.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,178.82 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,135.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $890.53 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $771.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $363.99 | 2020-2024 | |
| Sanofi-Aventis U.S. LLC | $319.30 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $299.20 | 2019-2023 | Xifaxan |
| Abbott Laboratories | $272.61 | 2021-2025 | Freestyle Libre 3, Eterna |
| Pfizer INC. | $198.33 | 2019-2025 | |
| Amarin Pharma, INC. | $197.43 | 2019-2021 | |
| Dexcom, INC. | $154.25 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $148.62 | 2019-2021 | |
| Astellas Pharma US INC | $141.81 | 2020-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.57 | 2021-2025 | Jardiance, Tradjenta |
| E.R. Squibb & Sons, L.L.C. | $91.43 | 2022-2023 | Eliquis, Camzyos |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $83.81 | 2019-2020 | |
| Esperion Therapeutics, INC. | $71.94 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $49.28 | 2020-2022 | |
| Kyowa Kirin, INC. | $38.48 | 2025 | |
| Sumitomo Pharma America, INC. | $37.31 | 2024-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $35.21 | 2019-2020 | |
| Exact Sciences Corporation | $34.04 | 2023-2025 | Cologuard Collection Kit |
| Evofem Biosciences, INC. | $32.60 | 2022-2025 | Phexxi, Solosec, Phexx |
| Inspire Medical Systems, INC. | $20.87 | 2023 | Inspire |
| Kowa Pharmaceuticals America, INC. | $19.64 | 2025 | Zoryve |
| Genentech USA, INC. | $17.98 | 2020 | |
| Sunovion Pharmaceuticals INC. | $16.78 | 2022 | |
| Currax Pharmaceuticals LLC | $15.72 | 2025 | Contrave |
| Idorsia Pharmaceuticals US INC | $14.68 | 2023 | Quviviq |
| Seqirus USA INC | $14.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maribeth Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.